Ensysce Biosciences
Quarterly Financials
| Values in thousands | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
Revenue | $960 | $1,882 | $493 | $1,371 |
Gross Profit | 954 | -2,461 | -551 | |
EBITDA | -3,562 | -2,762 | 18 | -1,730 |
EBIT | -3,568 | -2,769 | -3,722 | -3,480 |
Net Income | -3,556 | -2,767 | -3,729 | -1,733 |
Net Change In Cash | 960 | 1,882 | 493 | 1,371 |
Free Cash Flow | -3,500 | -1,525 | -1,989 | -2,706 |
Cash | 745 | 4,310,354,000 | 1,673 | 2,211 |
Basic Shares | 6,839 | 25,574 | 2,886 | 2,202 |
Annual Financials
| Values in thousands | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 |
|---|---|---|---|---|
Revenue | $5,066 | $5,210 | $2,231 | $2,523 |
Gross Profit | -2,009 | -5,357 | -17,312 | |
EBITDA | -10,150 | -6,729 | -10,718 | -24,222 |
EBIT | -10,157 | -6,730 | -10,717 | -24,222 |
Net Income | -10,175 | -7,987 | -10,613 | -24,961 |
Net Change In Cash | 5,066 | 5,210 | 2,231 | 2,523 |
Free Cash Flow | -7,806,292,000 | -7,502,700,000 | -10,779 | -17,887 |
Cash | 4,310 | 3,502 | 1,123 | 3,147 |
Basic Shares | 25,574 | 1,747 | 2,264 | 179 |
Earnings Calls
| Quarter | EPS |
|---|---|
2026-03-31 | -$0.52 |
2025-12-31 | -$0.75 |
2025-09-30 | -$1.29 |
2025-06-30 | -$0.79 |